JP2015511226A - 低酸素活性化プロドラッグ療法のための予測バイオマーカー - Google Patents

低酸素活性化プロドラッグ療法のための予測バイオマーカー Download PDF

Info

Publication number
JP2015511226A
JP2015511226A JP2014554975A JP2014554975A JP2015511226A JP 2015511226 A JP2015511226 A JP 2015511226A JP 2014554975 A JP2014554975 A JP 2014554975A JP 2014554975 A JP2014554975 A JP 2014554975A JP 2015511226 A JP2015511226 A JP 2015511226A
Authority
JP
Japan
Prior art keywords
level
patient
protein
sample
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014554975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511226A5 (enExample
Inventor
ハート，チャールズ
Original Assignee
スレッショルド ファーマシューティカルズ，インコーポレイテッド
スレッショルド ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレッショルド ファーマシューティカルズ，インコーポレイテッド, スレッショルド ファーマシューティカルズ，インコーポレイテッド filed Critical スレッショルド ファーマシューティカルズ，インコーポレイテッド
Publication of JP2015511226A publication Critical patent/JP2015511226A/ja
Publication of JP2015511226A5 publication Critical patent/JP2015511226A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014554975A 2012-01-31 2013-01-30 低酸素活性化プロドラッグ療法のための予測バイオマーカー Pending JP2015511226A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593249P 2012-01-31 2012-01-31
US61/593,249 2012-01-31
PCT/US2013/023921 WO2013116385A1 (en) 2012-01-31 2013-01-30 Predictive biomarker for hypoxia-activated prodrug therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017214327A Division JP2018052956A (ja) 2012-01-31 2017-11-07 低酸素活性化プロドラッグ療法のための予測バイオマーカー

Publications (2)

Publication Number Publication Date
JP2015511226A true JP2015511226A (ja) 2015-04-16
JP2015511226A5 JP2015511226A5 (enExample) 2016-03-17

Family

ID=48905801

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014554975A Pending JP2015511226A (ja) 2012-01-31 2013-01-30 低酸素活性化プロドラッグ療法のための予測バイオマーカー
JP2017214327A Withdrawn JP2018052956A (ja) 2012-01-31 2017-11-07 低酸素活性化プロドラッグ療法のための予測バイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017214327A Withdrawn JP2018052956A (ja) 2012-01-31 2017-11-07 低酸素活性化プロドラッグ療法のための予測バイオマーカー

Country Status (4)

Country Link
US (1) US20150005264A1 (enExample)
EP (1) EP2810076A4 (enExample)
JP (2) JP2015511226A (enExample)
WO (1) WO2013116385A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1896040T1 (sl) 2005-06-29 2012-12-31 Threshold Pharmaceuticals, Inc. Fosforamidatna alkilatorska predzdravila
JP2015500885A (ja) 2011-12-22 2015-01-08 スレッショルド ファーマシューティカルズ，インコーポレイテッド 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与
WO2015025283A2 (en) * 2013-08-20 2015-02-26 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Dual action carbonic anhydrase inhibitors
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
WO2016081547A1 (en) * 2014-11-19 2016-05-26 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
EP4549467A3 (en) * 2016-08-01 2025-07-23 ImmunoGenesis, Inc. Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
CN118076359A (zh) 2021-08-27 2024-05-24 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
CN117651548A (zh) 2021-08-27 2024-03-05 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN119384281A (zh) 2022-04-15 2025-01-28 深圳艾欣达伟医药科技有限公司 使用th-302单药或联用parp抑制剂治疗癌症的方法
WO2023226959A1 (zh) 2022-05-23 2023-11-30 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009288A2 (en) * 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026218T2 (en) * 2002-02-21 2016-05-30 Inst Virology MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice
EP1743038A4 (en) * 2004-05-04 2007-11-21 Bayer Healthcare MN / CA IX / CA9 AND KIDNEY CANCER PROGNOSIS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009288A2 (en) * 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ＢＲＩＴＩＳＨ ＪＯＵＲＮＡＬ ＯＦ ＣＡＮＣＥＲ, vol. 83, no. 12, JPN6016040005, 2000, pages 1589 - 1593, ISSN: 0003423196 *
ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, vol. 61, no. 13, JPN6016040006, 2001, pages 5262 - 5267, ISSN: 0003423197 *
ＣＬＩＮＩＣＡＬ ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, vol. [online], JPN6016039998, 19 December 2011 (2011-12-19), pages 10 - 1158, ISSN: 0003423192 *
ＣＬＩＮＩＣＡＬ ＣＡＮＣＥＲ ＲＥＳＥＡＲＣＨ, vol. 14, no. 21, JPN6016040003, 2008, pages 7110 - 7115, ISSN: 0003423195 *
ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＪＯＵＲＮＡＬ ＯＦ ＲＡＤＩＡＴＩＯＮ ＯＮＣＯＬＯＧＹ，ＢＩＯＬＯＧ, vol. 73, no. 4, JPN6016039999, 2009, pages 1177 - 1186, ISSN: 0003423193 *
ＪＯＵＲＮＡＬ ＯＦ ＵＲＯＬＯＧＹ, vol. 180, no. 2, JPN6016040001, 2008, pages 510 - 514, ISSN: 0003423194 *

Also Published As

Publication number Publication date
EP2810076A1 (en) 2014-12-10
JP2018052956A (ja) 2018-04-05
WO2013116385A1 (en) 2013-08-08
US20150005264A1 (en) 2015-01-01
EP2810076A4 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
JP2018052956A (ja) 低酸素活性化プロドラッグ療法のための予測バイオマーカー
Leithner et al. Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model–role of tumor stroma cells
JP6446381B2 (ja) ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法
US10071109B2 (en) Predictive biomarker for hypoxia-activated prodrug therapy
Wu et al. ASC contributes to metastasis of oral cavity squamous cell carcinoma
Galli et al. Neuropeptide Y as a biomarker and therapeutic target for neuroblastoma
WO2014184679A2 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
US10760130B2 (en) Predictive biomarker for hypoxia-activated prodrug therapy
US20140030257A1 (en) Agtr1 as a marker for bevacizumab combination therapies
KR101925125B1 (ko) Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
Dmitrenko et al. Reduction of the transcription level of the mitochondrial genome in human glioblastoma
Huang et al. Knockdown of MUC16 (CA125) enhances the migration and invasion of hepatocellular carcinoma cells
CN101768214B (zh) 一种人肿瘤标志物-Tim17多肽及其用途
Zhang et al. The diagnostic accuracy of exosomes for glioma: a meta-analysis
CN115807082A (zh) lncRNA LINREP在胶质瘤诊断、预后和治疗中的应用
JP6397765B2 (ja) プロテアソーム阻害剤に応答するバイオマーカー
JP2012085554A (ja) 乳がんのサブタイプの判別方法
TWI798532B (zh) Ｋｄｍ５ａ基因和ａｔｒｘ基因的應用
EP3460476B1 (en) Biomarker composition comprising lrp-1 as active ingredient, for diagnosis of radiation-resistant cancer or prediction of radiation therapy prognosis
JP2025524980A (ja) 乳がんの同定および処置方法
US20150011411A1 (en) Biomarkers of cancer
EP1988164A1 (en) Method of testing sensitivity of solid cancer against tyrosine kinase inhibitor and test kit therefor
WO2021105886A2 (en) Use of protease serine 21 (prss21) antigen testing in the diagnosis and treatment of acute myeloid leukemia
Mirtavoos-Mahyari et al. Cell free tumoral DNA versus paraffin block epidermal growth factor receptor mutation detection in patients with non-small cell lung cancer
CN117425827A (zh) 用于诊断癌症的试剂盒及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180417